Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7740849B2 · kind B2 · utility
7Cited by
29References
37Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 31, 2006 |
| Grant date | Jun 22, 2010 |
| Priority date | — |
| Expiry date | Nov 21, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/368
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sFlt-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.